Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ETD001 in Healthy Volunteers
NCT04926701Phase 1Completed
- Sponsor
- Enterprise Therapeutics
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ETD001 in cystic fibrosis (CF) (3 arms), sponsored by Enterprise Therapeutics. Primary endpoints: Number of participants reporting one or more treatment emergent adverse event, Number of participants who discontinue due to an adverse event and 4 more. Started Jun 2021; status: completed.
02
Drugs
ETD001
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04926701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926701.